Amedeo Smart

Free Medical Literature Service



Bladder Cancer

  Free Subscription

Articles published in
Clin Cancer Res
    July 2018
  1. LI Q, Damish A, Frazier ZJ, Liu D, et al
    ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer.
    Clin Cancer Res. 2018 Jul 6. pii: 1078-0432.CCR-18-1001.
    >> Share

    June 2018
  2. LELO A, Prip F, Harris BT, Solomon D, et al
    STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer.
    Clin Cancer Res. 2018 Jun 28. pii: 1078-0432.CCR-17-3244.
    >> Share

    March 2018
  3. FU H, Zhu Y, Wang Y, Liu Z, et al
    Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle Invasive Bladder Cancer.
    Clin Cancer Res. 2018 Mar 7. pii: 1078-0432.CCR-17-2687.
    >> Share

    January 2018
  4. VAN KESSEL KE, van der Keur KA, Dyrskjot L, Algaba F, et al
    Molecular markers increase precision of the European Association of Urology non-muscle invasive bladder cancer progression risk groups.
    Clin Cancer Res. 2018 Jan 24. pii: 1078-0432.CCR-17-2719.
    >> Share

    December 2017
  5. CHEN CH, Changou C, Hsieh TH, Lee YC, et al
    Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer.
    Clin Cancer Res. 2017 Dec 8. pii: 1078-0432.CCR-17-2066.
    >> Share

    September 2017
  6. MARTINEZ VG, Rubio C, Martinez-Fernandez M, Segovia C, et al
    BMP4 induces M2 macrophage polarization and favors tumor progression in bladder cancer.
    Clin Cancer Res. 2017 Sep 19. pii: clincanres.1004.2017.
    >> Share

  7. WU S, Zheng J, Li Y, Yu H, et al
    A Radiomics Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer.
    Clin Cancer Res. 2017 Sep 5. pii: clincanres.1510.2017.
    >> Share

    August 2017
  8. KATES M, Date A, Yoshida T, Afzal U, et al
    Preclincial Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer.
    Clin Cancer Res. 2017 Aug 14. pii: clincanres.1082.2017.
    >> Share

  9. ZENG S, Zhu Y, Ma AH, Yu W, et al
    The Phosphatidylinositol 3-kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.
    Clin Cancer Res. 2017 Aug 14. pii: clincanres.0033.2017.
    >> Share

  10. WEN T, Yang Z, He L, Lin K, et al
    The KMT1A-GATA3-STAT3 circuit is a novel self-renewal signaling of human bladder cancer stem cells.
    Clin Cancer Res. 2017 Aug 1. pii: clincanres.0882.2017.
    >> Share

    July 2017
  11. VANDEKERKHOVE GR, Todenhofer T, Annala M, Struss WJ, et al
    <span style="font-weight: 400;">Circulating tumor DNA reveals clinically-actionable somatic genome of metastatic bladder cancer</span>.
    Clin Cancer Res. 2017 Jul 31. pii: clincanres.1140.2017.
    >> Share

    April 2017
  12. YANG L, Taylor J, Eustace A, Irlam J, et al
    A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High Risk Bladder Cancer Patients.
    Clin Cancer Res. 2017 Apr 11. pii: clincanres.0038.2017.
    >> Share

    February 2017
  13. SIN ML, Mach KE, Sinha R, Wu F, et al
    Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics.
    Clin Cancer Res. 2017 Feb 13. pii: clincanres.2610.2016.
    >> Share

    January 2017
  14. WANG WJ, Li CF, Chu YY, Wang YH, et al
    Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder.
    Clin Cancer Res. 2017;23:503-513.
    >> Share

    November 2016
  15. INMAN BA, Longo TA, Ramalingam S, Harrison MR, et al
    Atezolizumab: a PD-L1 blocking antibody for bladder cancer.
    Clin Cancer Res. 2016 Nov 30. pii: clincanres.1417.2016.
    >> Share

    August 2016
  16. DERRE L, Cesson V, Lucca I, Cerantola Y, et al
    Intravesical Bacillus Calmette Guerin combined with a cancer-vaccine increases local T-cell responses in non-muscle-invasive bladder cancer patients.
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.1189.2016.
    >> Share

    May 2016
  17. ZHANG H, Prado K, Zhang KX, Peek EM, et al
    Biased Expression of the FOXP3Delta3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance.
    Clin Cancer Res. 2016 May 17. pii: clincanres.2581.2015.
    >> Share

    March 2016
  18. FRANTZI M, Van Kessel KE, Zwarthoff EC, Marquez M, et al
    Development and validation of urine-based peptide biomarker panels for detecting bladder cancer in a multi-center study.
    Clin Cancer Res. 2016 Mar 29. pii: clincanres.2715.2015.
    >> Share

  19. GUIN S, Ru Y, Agarwal N, Lew CR, et al
    Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis.
    Clin Cancer Res. 2016;22:1274-83.
    >> Share

    January 2016
  20. HAYASHI T, Gust KM, Wyatt AW, Goriki A, et al
    Clin Cancer Res. 2016 Jan 14. pii: clincanres.2360.2015.
    >> Share

    December 2015
  21. GHASEMZADEH A, Bivalacqua TJ, Hahn NM, Drake CG, et al
    New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.
    Clin Cancer Res. 2015 Dec 18. pii: clincanres.1135.2015.
    >> Share

    November 2015
  22. NOGUCHI M, Matsumoto K, Uemura H, Arai G, et al
    An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy.
    Clin Cancer Res. 2015.
    >> Share

    October 2015
  23. KIM HS, Jeong CW, Kwak C, Kim HH, et al
    Pathological T0 following cisplatin-based neo-adjuvant chemotherapy for muscle-invasive bladder cancer: a network meta-analysis.
    Clin Cancer Res. 2015 Oct 26. pii: clincanres.1208.2015.
    >> Share

  24. KIM J, Akbani R, Creighton CJ, Lerner SP, et al
    Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise.
    Clin Cancer Res. 2015;21:4514-24.
    >> Share

    August 2015
  25. LEE SR, Roh YG, Kim SK, Lee JS, et al
    Activation of EZH2 and SUZ12 regulated by E2F1 predicts the disease progression and aggressive characteristics of bladder cancer.
    Clin Cancer Res. 2015 Aug 12. pii: clincanres.2680.2014.
    >> Share

    March 2015
  26. DRONCA RS, Dong H
    Immunomodulatory antibody therapy of cancer: the closer, the better.
    Clin Cancer Res. 2015;21:944-6.
    >> Share

  27. MANGSBO SM, Broos S, Fletcher E, Veitonmaki N, et al
    The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity.
    Clin Cancer Res. 2015;21:1115-26.
    >> Share

    January 2015
  28. SVATEK RS, Zhao XR, Morales EE, Jha MK, et al
    Sequential intravesical mitomycin plus Bacillus Calmette-Guerin for non-muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trial.
    Clin Cancer Res. 2015;21:303-11.
    >> Share

  29. SHAPIRO GI, Kwak E, Dezube BJ, Yule M, et al
    First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors.
    Clin Cancer Res. 2015;21:87-97.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016